Greykasell Wealth Strategies’s AstraZeneca AZN Stock Holding History

Greykasell Wealth Strategies’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131K	Hold	690	–	–	0.05%	174
2026 Q1	$136K	Hold	690	–	–	0.05%	168
2025 Q4	$127K	Hold	690	–	–	0.05%	170
2025 Q3	$106K	Hold	690	–	–	0.04%	172
2025 Q2	$96.4K	Hold	690	–	–	0.05%	163
2025 Q1	$101K	Buy	+690	New	+$99.8K	0.05%	156

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Greykasell Wealth Strategies's AZN Position: Q2 2026 in Review

Greykasell Wealth Strategies held its AstraZeneca (AZN) position steady in Q2 2026 at 690 shares worth $131K. The position accounts for 0.05% of the portfolio, ranked #174.

Greykasell Wealth Strategies first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $136K in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Greykasell Wealth Strategies held 690 shares of AstraZeneca worth $131K as of Q2 2026.
Greykasell Wealth Strategies left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.05% of Greykasell Wealth Strategies's portfolio in Q2 2026, its #174 holding.
Greykasell Wealth Strategies first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
Greykasell Wealth Strategies's AstraZeneca position peaked at $136K in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2026, filed 11 Aug 2026.